FCM data from 40 controls and 15 LGw/oRS patients in the second cohort (prospective analysis)
. | Controls . | . | . | LGw/oRS patients . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| FCM data . | Mean . | SD . | No. outside RR* . | Mean . | SD . | No. outside RR* . | ||||
| Hematogones in all CD34+ cells | 13.94 | 8.22 | 3 | 5.68 | 7.66 | 10 | ||||
| CD34+ myeloblasts in all nucleated cells | 1.11 | 0.54 | 1 | 2.07 | 1.63 | 4 | ||||
| Antigen expression on CD34+ myeloblasts | ||||||||||
| Lymphoid antigens | ||||||||||
| CD2 | 1.04 | 0.12 | 0 | 1.02 | 0.14 | 0 | ||||
| CD4 | 1.62 | 0.40 | 0 | 2.19 | 1.70 | 3 | ||||
| CD10 | 0.96 | 0.12 | 0 | 0.89 | 0.13 | 0 | ||||
| CD56 | 0.91 | 0.06 | 0 | 1.05 | 0.18 | 4 | ||||
| Myeloid antigens | ||||||||||
| CD11b | 1.61 | 0.33 | 0 | 1.46 | 0.55 | 1 | ||||
| CD13 | 10.10 | 4.14 | 2 | 20.98 | 15.93 | 6 | ||||
| CD15 | 2.33 | 0.62 | 0 | 3.06 | 1.98 | 3 | ||||
| CD33 | 5.34 | 1.46 | 0 | 9.38 | 5.56 | 2 | ||||
| Immaturity-related antigens | ||||||||||
| CD117 | 10.19 | 3.50 | 1 | 20.28 | 13.94 | 7 | ||||
| CD123 | 1.43 | 0.36 | 0 | 1.79 | 0.68 | 0 | ||||
| CD133 | 2.17 | 0.94 | 2 | 2.62 | 1.52 | 3 | ||||
. | Controls . | . | . | LGw/oRS patients . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| FCM data . | Mean . | SD . | No. outside RR* . | Mean . | SD . | No. outside RR* . | ||||
| Hematogones in all CD34+ cells | 13.94 | 8.22 | 3 | 5.68 | 7.66 | 10 | ||||
| CD34+ myeloblasts in all nucleated cells | 1.11 | 0.54 | 1 | 2.07 | 1.63 | 4 | ||||
| Antigen expression on CD34+ myeloblasts | ||||||||||
| Lymphoid antigens | ||||||||||
| CD2 | 1.04 | 0.12 | 0 | 1.02 | 0.14 | 0 | ||||
| CD4 | 1.62 | 0.40 | 0 | 2.19 | 1.70 | 3 | ||||
| CD10 | 0.96 | 0.12 | 0 | 0.89 | 0.13 | 0 | ||||
| CD56 | 0.91 | 0.06 | 0 | 1.05 | 0.18 | 4 | ||||
| Myeloid antigens | ||||||||||
| CD11b | 1.61 | 0.33 | 0 | 1.46 | 0.55 | 1 | ||||
| CD13 | 10.10 | 4.14 | 2 | 20.98 | 15.93 | 6 | ||||
| CD15 | 2.33 | 0.62 | 0 | 3.06 | 1.98 | 3 | ||||
| CD33 | 5.34 | 1.46 | 0 | 9.38 | 5.56 | 2 | ||||
| Immaturity-related antigens | ||||||||||
| CD117 | 10.19 | 3.50 | 1 | 20.28 | 13.94 | 7 | ||||
| CD123 | 1.43 | 0.36 | 0 | 1.79 | 0.68 | 0 | ||||
| CD133 | 2.17 | 0.94 | 2 | 2.62 | 1.52 | 3 | ||||
Mean, SD, and RR are percentages (hematogones in all CD34+ cells and CD34+ myeloblasts in all nucleated cells) or RMFI (other parameters). For the controls, n = 40; for LGw/oRS patients, n = 15.
Number of patients or controls outside RR, out of the patients or controls analyzed. RRs are the same as those shown in Table 2.